Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Lally

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Brain, Behavior, and Immunity|October 13, 2023
Changes in immunoglobulin levels during clozapine treatment in schizophreniaKira Griffiths, Maria Ruiz Mellado, Raymond Chung, et al.
BMC Psychiatry|December 30, 2017
Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)Fiona Gaughran, Daniel Stahl, Khalida Ismail, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Schizophrenia Research|July 30, 2017
Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosisOlesya Ajnakina, John Lally, Marta Di Forti, et al.
Schizophrenia Research|December 8, 2023
Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UKCarlos De Las Cuevas, Emilio J Sanz, Jason A Gross, et al.
Schizophrenia Research|January 1, 2016
Substance use, medication adherence and outcome one year following a first episode of psychosisMarco Colizzi, Elena Carra, Sara Fraietta, et al.
Schizophrenia Research|July 31, 2017
Hyperprolactinaemia in first episode psychosis - A longitudinal assessmentJohn Lally, Olesya Ajnakina, Brendon Stubbs, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
Schizophrenia Research|May 23, 2019
Differential gene expression analysis in blood of first episode psychosis patientsDaniel J Leirer, Conrad O Iyegbe, Marta Di Forti, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Brain, Behavior, and Immunity|October 13, 2023
Changes in immunoglobulin levels during clozapine treatment in schizophreniaKira Griffiths, Maria Ruiz Mellado, Raymond Chung, et al.
BMC Psychiatry|December 30, 2017
Randomised control trial of the effectiveness of an integrated psychosocial health promotion intervention aimed at improving health and reducing substance use in established psychosis (IMPaCT)Fiona Gaughran, Daniel Stahl, Khalida Ismail, et al.
Schizophrenia Bulletin|January 5, 2021
Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant SchizophreniaGrant McQueen, Kyra-Verena Sendt, Amy Gillespie, et al.
Schizophrenia (Heidelberg, Germany)|March 3, 2022
Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophreniaFanni Krajner, Laila Hadaya, Grant McQueen, et al.
Schizophrenia Research|July 30, 2017
Utilising symptom dimensions with diagnostic categories improves prediction of time to first remission in first-episode psychosisOlesya Ajnakina, John Lally, Marta Di Forti, et al.
Schizophrenia Research|December 8, 2023
Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UKCarlos De Las Cuevas, Emilio J Sanz, Jason A Gross, et al.
Schizophrenia Research|January 1, 2016
Substance use, medication adherence and outcome one year following a first episode of psychosisMarco Colizzi, Elena Carra, Sara Fraietta, et al.
Schizophrenia Research|July 31, 2017
Hyperprolactinaemia in first episode psychosis - A longitudinal assessmentJohn Lally, Olesya Ajnakina, Brendon Stubbs, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
Schizophrenia Research|May 23, 2019
Differential gene expression analysis in blood of first episode psychosis patientsDaniel J Leirer, Conrad O Iyegbe, Marta Di Forti, et al.
Pageof 10